Management of Cytomegalovirus Infections in the Era of the Novel Antiviral Players, Letermovir and Maribavir
Cytomegalovirus (CMV) infections may increase morbidity and mortality in immunocompromised patients. Until recently, standard antiviral drugs against CMV were limited to viral DNA polymerase inhibitors (val)ganciclovir, foscarnet and cidofovir with a risk for cross-resistance. These drugs may also c...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Infectious Disease Reports |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2036-7449/16/1/5 |